Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina

This study has been completed.
Sponsor:
Collaborator:
North Carolina Division of Public Health
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier:
NCT01544764
First received: February 24, 2012
Last updated: December 16, 2013
Last verified: December 2013

February 24, 2012
December 16, 2013
April 2011
December 2012   (final data collection date for primary outcome measure)
Change in Vaccination Rate: HPV vaccine initiation among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
We will gather practice-specific rates of coverage for adolescents (age 11-12) for the first dose of human papillomavirus (HPV) vaccine at baseline and 5 months follow-up.
Change in Vaccination Rate [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]

We will gather practice-specific rates of coverage for adolescents (age 11-18) for tetanus, diphtheria, and pertussis booster; measles, mumps, rubella vaccine; meningococcal vaccine; hepatitis B vaccine; varicella vaccine; and human papillomavirus vaccine; as well as the combination of vaccines.

We will also calculate practice-specific instances of missed opportunities to vaccinate an adolescent (age 11-18), that is, instances when an adolescent visited a provider and received at least one vaccine but did not receive other vaccines he/she was eligible to receive.

Complete list of historical versions of study NCT01544764 on ClinicalTrials.gov Archive Site
  • Change in Vaccination Rate: HPV vaccine initiation among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 13-18) for the first dose of human papillomavirus (HPV) vaccine at baseline and 5 months follow-up.
  • Change in Vaccination Rate: Tdap vaccine among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 11-12) for tetanus, diphtheria, and pertussis booster (Tdap) at baseline and 5 months follow-up.
  • Change in Vaccination Rate: Tdap vaccine among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 13-18) for tetanus, diphtheria, and pertussis booster (Tdap) at baseline and 5 months follow-up.
  • Change in Vaccination Rate: Meningitis vaccine among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 11-12) for meningococcal conjugate (i.e., meningitis vaccine) at baseline and 5 months follow-up.
  • Change in Vaccination Rate: Meningitis vaccine among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 13-18) for meningococcal conjugate (i.e., meningitis vaccine) at baseline and 5 months follow-up.
  • Change in Vaccination Rate: HPV vaccine completion among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 11-12) for the third and final dose of human papillomavirus (HPV) vaccine at baseline and 5 months follow-up.
  • Change in Vaccination Rate: HPV vaccine completion among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (age 13-18) for the third and final dose of human papillomavirus (HPV) vaccine at baseline and 5 months follow-up.
Intervention Evaluation [ Time Frame: 5 months follow-up ] [ Designated as safety issue: No ]
Participating practices will provide feedback on the intervention, including costs, perceptions of the intervention, use of recommended practices, etc., to facilitate a process evaluation of the program.
  • Change in Vaccination Rate: MMR among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 11-12) for measles, mumps, and rubella (MMR) vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact MMR coverage.
  • Change in Vaccination Rate: MMR among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 13-18) for measles, mumps, and rubella (MMR) vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact MMR coverage.
  • Change in Vaccination Rate: Hepatitis B vaccine among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 11-12) for hepatitis B vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact hepatitis B vaccine coverage.
  • Change in Vaccination Rate: Hepatitis B vaccine among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 13-18) for hepatitis B vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact hepatitis B vaccine coverage.
  • Change in Vaccination Rate: Varicella vaccine among 11-12 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 11-12) for varicella vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact varicella vaccine coverage.
  • Change in Vaccination Rate: Varicella vaccine among 13-18 year olds [ Time Frame: Baseline and 5 months follow-up ] [ Designated as safety issue: No ]
    We will gather practice-specific rates of coverage for adolescents (ages 13-18) for varicella vaccine at baseline and 5 months follow-up. This is a childhood vaccine that is not targeted for adolescents; however the intervention may impact varicella vaccine coverage.
Not Provided
 
Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX) in North Carolina
Examining Adolescent Assessment, Feedback, Incentive, and Exchange (AFIX)

The North Carolina Immunization Branch will evaluate the use of the CDC program to improve adolescent vaccination practices (called Assessment, Feedback, Incentives, and eXchanges, or AFIX). This evaluation is the first of its kind in the nation and may have a profound impact on prevention.

AFIX has four major components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.

This program will evaluate the effectiveness of AFIX visits on affecting provider practices to increase adolescent (age 11-18) immunization. Visits include discussion of that practice's immunization rates and strategies for improving rates. The investigators will compare the changes, from baseline to 5 months, in immunization for practices receiving virtual visits (webinars), in-person visits, and no visits (control group). Thirty practices will be randomly assigned to each intervention type. The main outcomes of this study are practice-wide uptake rates of several adolescent vaccines (Tdap, HPV, and MCV4) as well as pre- and post-AFIX visit surveys focusing on recall tactics utilized by each practice. Data will be collected on practices with at least 200 adolescent patients (note: there is no patient-level data collected in this study).

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Health Services Research
  • Adolescent Health Services
  • Immunization
Other: Assessment , Feedback, Incentives, and eXchange Program
The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
  • No Intervention: Control
    This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. Practices in this arm were randomly assigned to receive no AFIX visit.
  • Experimental: AFIX In-Person Visit

    This arm includes 30 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received an in-person AFIX visit from a North Carolina Immunization Branch employee.

    Intervention:

    Other: Assessment , Feedback, Incentives, and eXchange Program

    Intervention: Other: Assessment , Feedback, Incentives, and eXchange Program
  • Experimental: AFIX Webinar Visit

    This arm includes 31 health centers in North Carolina with at least 200 adolescent (age 11-18) patients. These practices received a webinar during which a North Carolina Immunization Branch employee completed the components of an AFIX visit.

    Intervention:

    Other: Assessment , Feedback, Incentives, and eXchange Program

    Intervention: Other: Assessment , Feedback, Incentives, and eXchange Program

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
91
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Pediatric and/or family practices participating in the North Carolina Immunization Program
  • A minimum of 200 active adolescent patients
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01544764
2011-3
No
University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
North Carolina Division of Public Health
Principal Investigator: Amanda Dayton, MA DPH/WCH/Immunization
Principal Investigator: Amy Grimshaw, MS, MSW DPH/WCH/Immunization
Study Director: Noel T Brewer, PhD University of North Carolina, Chapel Hill
University of North Carolina, Chapel Hill
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP